{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:45:49Z","timestamp":1790772349369,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jcyt.2023.01.002","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T15:25:20Z","timestamp":1676129120000},"page":"490-501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["T-cell engineered with a fully humanized B-cell maturation antigen-specific T-cell antigen coupler receptor effectively target multiple myeloma"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1294-4853","authenticated-orcid":false,"given":"Ksenia","family":"Bezverbnaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne A.","family":"Hammill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojana","family":"Bojovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella","family":"Groisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2019-5071","authenticated-orcid":false,"given":"Christopher L.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Aarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle L.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Rill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5565-7884","authenticated-orcid":false,"given":"Stacey X.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas G.","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W.","family":"Helsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2874-6886","authenticated-orcid":false,"given":"Jonathan L.","family":"Bramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2023.01.002_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.925818","article-title":"Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm","volume":"12","author":"Keller","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.jcyt.2023.01.002_bib0002","first-page":"249","article-title":"FDA approves second BCMA-targeted CAR-T cell therapy","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.jcyt.2023.01.002_bib0003","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2023.01.002_bib0004","doi-asserted-by":"crossref","unstructured":"Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):eaau7746.","DOI":"10.1126\/scitranslmed.aau7746"},{"issue":"5","key":"10.1016\/j.jcyt.2023.01.002_bib0005","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2023.01.002_bib0006","doi-asserted-by":"crossref","unstructured":"Gogishvili T, Danhof S, Prommersberger S, et al. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes. Blood. 2017;130(26):2838-2847.","DOI":"10.1182\/blood-2017-04-778423"},{"issue":"25","key":"10.1016\/j.jcyt.2023.01.002_bib0007","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.jcyt.2023.01.002_bib0008","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.jcyt.2023.01.002_bib0009","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jcyt.2023.01.002_bib0010","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1038\/s41467-018-05395-y","article-title":"The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity","volume":"9","author":"Helsen","year":"2018","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.jcyt.2023.01.002_bib0011","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jcyt.2021.05.007","article-title":"Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma","volume":"23","author":"Bezverbnaya","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2023.01.002_bib0012","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40364-020-00197-1","article-title":"Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies","volume":"8","author":"Nie","year":"2020","journal-title":"Biomark Res"},{"issue":"6","key":"10.1016\/j.jcyt.2023.01.002_bib0013","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.jcyt.2023.01.002_bib0014","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"10.1016\/j.jcyt.2023.01.002_bib0015","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/protein\/6.8.989","article-title":"An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability","volume":"6","author":"Whitlow","year":"1993","journal-title":"Protein Eng"},{"issue":"10","key":"10.1016\/j.jcyt.2023.01.002_bib0016","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/protein\/gzs024","article-title":"Computer-aided antibody design","volume":"25","author":"Kuroda","year":"2012","journal-title":"Protein Eng Des Sel"},{"issue":"8","key":"10.1016\/j.jcyt.2023.01.002_bib0017","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/protein\/14.8.529","article-title":"Design of the linkers which effectively separate domains of a bifunctional fusion protein","volume":"14","author":"Arai","year":"2001","journal-title":"Protein Eng"},{"issue":"3","key":"10.1016\/j.jcyt.2023.01.002_bib0018","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1128\/cdli.3.3.301-304.1996","article-title":"Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly- and oligoclonal lymphocyte activation","volume":"3","author":"Simms","year":"1996","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.jcyt.2023.01.002_bib0019","unstructured":"Helsen CW, Bramson J, Dvorkin-Gheva A, Denisova G, Bezverbnaya K, Mwawasi KA, inventors; McMaster University, assignee, T cell antigen coupler with Y177T mutation and methods of uses thereof. USA patent 11198737. 2021."},{"issue":"3","key":"10.1016\/j.jcyt.2023.01.002_bib0020","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/j.1365-2141.2000.02413.x","article-title":"Expression and production of interleukin 10 in human myeloma cell lines","volume":"111","author":"Otsuki","year":"2000","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.jcyt.2023.01.002_bib0021","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jcyt.2023.01.002_bib0022","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/17474086.2022.2081147","article-title":"Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma","volume":"15","author":"Davis","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jcyt.2023.01.002_bib0023","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","author":"Martin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jcyt.2023.01.002_bib0024","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40259-018-0299-9","article-title":"Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies","volume":"32","author":"Husain","year":"2018","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.jcyt.2023.01.002_bib0025","doi-asserted-by":"crossref","first-page":"14366","DOI":"10.1038\/s41598-017-14749-3","article-title":"Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity","volume":"7","author":"Park","year":"2017","journal-title":"Sci Rep"},{"issue":"17","key":"10.1016\/j.jcyt.2023.01.002_bib0026","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jcyt.2023.01.002_bib0027","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","article-title":"High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model","volume":"6","author":"Richman","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jcyt.2023.01.002_bib0028","doi-asserted-by":"crossref","unstructured":"Ying Z, Huang XF, Xiang X, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25(6):947-953.","DOI":"10.1038\/s41591-019-0421-7"},{"issue":"1","key":"10.1016\/j.jcyt.2023.01.002_bib0029","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2023.01.002_bib0030","first-page":"705","article-title":"Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date","volume":"16","author":"Si","year":"2020","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"10.1016\/j.jcyt.2023.01.002_bib0031","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40164-021-00209-2","article-title":"Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy","volume":"10","author":"Zhang","year":"2021","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"10.1016\/j.jcyt.2023.01.002_bib0032","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"issue":"38","key":"10.1016\/j.jcyt.2023.01.002_bib0033","doi-asserted-by":"crossref","first-page":"14342","DOI":"10.1073\/pnas.0804105105","article-title":"Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer","volume":"105","author":"Rabinovich","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.jcyt.2023.01.002_bib0034","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jmb.2012.11.037","article-title":"CDR-H3 diversity is not required for antigen recognition by synthetic antibodies","volume":"425","author":"Persson","year":"2013","journal-title":"J Mol Biol"},{"issue":"24","key":"10.1016\/j.jcyt.2023.01.002_bib0035","doi-asserted-by":"crossref","first-page":"8898","DOI":"10.1073\/pnas.84.24.8898","article-title":"Helix stabilization by Glu-...Lys+ salt bridges in short peptides of de novo design","volume":"84","author":"Marqusee","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2023.01.002_bib0036","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40425-015-0099-4","article-title":"Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors","volume":"3","author":"Hammill","year":"2015","journal-title":"J Immunother Cancer"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:48:32Z","timestamp":1761443312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324923000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1465324923000063"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.01.002","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T-cell engineered with a fully humanized B-cell maturation antigen-specific T-cell antigen coupler receptor effectively target multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}